Although adiponectin exhibits significant anti-diabetic, anti-inflammatory and anti-atherogenic properties2,3, CKD patients, who exhibit a serum adiponectin level approximately 3-fold higher than the reported value of 5.4 ± 2.3 μg/mL in non-CKD subjects1, are at higher risk for all-cause mortality. Here, ADIPOQ is linked to chronic kidney disease.